please help improve it or discuss these issues on the talk page . learn how and when to remove these template messages the topic of this article may not meet wikipedia s notability guidelines for companies and organizations . please help to establish notability by citing reliable secondary sources that are independent of the topic and provide significant coverage of it beyond its mere trivial mention . if notability can not be established the article is likely to be merged redirected or deleted . find sources discovery laboratories news newspapers books scholar jstor free images february 2014 learn how and when to remove this template message this article relies too much on references to primary sources . please improve this by adding secondary or tertiary sources . february 2014 learn how and when to remove this template message this article needs additional citations for verification . please help improve this article by adding citations to reliable sources . unsourced material may be challenged and removed . february 2014 learn how and when to remove this template message this article is an orphan as no other articles link to it . please introduce links to this page from related articles ; try the find link tool for suggestions . february 2014 learn how and when to remove this template message discovery laboratories inc type public traded as nasdaq dsco industry healthcare biotechnology founded 1992 headquarters warrington pennsylvania united states key people john g. cooper chief executive officer president chief financial officer and director thomas f. miller ph.d. chief operating officer mr. john a. tattory chief accounting officer dec 31 2012 services respiratory critical care revenue 510.00 k sep 30 2013 number of employees 119 sep 30 2013 website www.discoverylabs.com discovery laboratories inc nasdaq dsco is an american company which was set up in 1992 and now is based in warrington pennsylvania developing drug products pulmonary medicine for patients with respiratory disease . the company joined an alliance with laboratorios del dr. esteve s.a. 1 contents 1 products and services 2 research and development 3 references 4 external links products and services edit the major products of the company are surfaxin based on its capillary aerosol generating technology and aerosurf . surfaxin is a synthetic peptide containing kl4 surfactant similar to pulmonary surfactant which is naturally in the lung for normal respiratory function . the drug is delivered by its capillary aerosol generating technology to the lung . aerosurf is a drug device combination to prevent respiratory distress syndrome rds in premature infants . in addition the company also provides afectair devices disposable aerosol conducting airway connectors . 2 research and development edit in november 2013 discovery laboratories began its phase ii clinical program of aerosolized kl4 since u.s. food and drug administration fda had cleared the investigational new drug ind application . the phase ii consists of two steps to evaluate the safety and tolerability of the drug and determine the optimal dose for premature infants with respiratory distress syndrome rds 3 in october 2013 discovery laboratories received the agreement of updating surfaxin lucinactant intratracheal suspension from the u.s. food and drug administration fda to prevent respiratory distress syndrome rds in premature infants . 4 in september 2012 discovery laboratories started the four research projects to explore the kl4 surfactant technology for acute lung injury ali . these projects are funded through government sponsored biodefense related initiatives under the project bioshield act of 2004 and the pandemic and all hazards preparedness act of 2006 . 5 references edit business summary . products overview . discovery labs receives fda clearance of ind to initiate aerosurf phase 2 clinical program . discovery labs announces fda approval of surfaxin lucinactant updated product specifications . discovery labs initiates research projects with leading research institutions and us government agencies to assess kl 4 surfactant utility in acute lung injury . external links edit official website retrieved from https en.wikipedia.org w index.php title discovery laboratories & oldid 714723990 categories companies established in 1992companies listed on nasdaqhidden categories articles with topics of unclear notability from february 2014all articles with topics of unclear notabilityarticles lacking reliable references from february 2014all articles lacking reliable referencesarticles needing additional references from february 2014all articles needing additional referencesorphaned articles from february 2014all orphaned articles navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page print export create a bookdownload as pdfprintable version languages add links this page was last modified on 11 april 2016 at 13 28 . text is available under the creative commons attribution sharealike license ; additional terms may apply . by using this site you agree to the terms of use and privacy policy . wikipedia is a registered trademark of the wikimedia foundation inc. a non profit organization . privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view